Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression. Local targets link to admitted publications; unresolved targets remain external evidence.
Exploring the next generation of antibody-drug conjugates
10.1038/s41571-023-00850-2 · 2024 · External reference
Antibody-drug conjugates come of age in oncology
10.1038/s41573-023-00709-2 · 2023 · External reference
Antibody-drug conjugates--an emerging class of cancer treatment
10.1038/bjc.2015.435 · 2016 · External reference
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
2022 · External reference
Tumor microenvironment as a therapeutic target in cancer
10.1016/j.pharmthera.2020.107753 · 2021 · External reference
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
10.1186/s12943-024-01963-7 · 2024 · External reference
Antibody-drug conjugates: beyond current approvals and potential future strategies
10.37349/etat.2022.00082 · 2022 · External reference
First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors
10.1158/1078-0432.ccr-20-4513 · 2021 · External reference
Antibody-drug conjugates: prospects for the next generation
10.1016/j.drudis.2024.104241 · 2024 · External reference
The journey of antibody–drug conjugates: lessons learned from 40 years of development
10.1158/2159-8290.cd-24-0708 · 2024 · External reference
The therapeutic window of antibody drug conjugates: a dogma in need of revision
10.1016/j.ccell.2022.09.016 · 2022 · External reference
Development of and insights from systems pharmacology models of antibody-drug conjugates
10.1002/psp4.12833 · 2022 · External reference
Modeling to capture bystander-killing effect by released payload in target positive tumor cells
10.1186/s12885-019-5336-7 · 2019 · External reference
Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy
10.1039/c7me00093f · 2018 · External reference
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
10.1007/s10928-023-09884-6 · 2024 · External reference
Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
10.1007/s10928-012-9276-y · 2012 · External reference
A “dual” cell-level systems PK-PD model to characterize the bystander effect of ADC
10.1016/j.xphs.2019.01.034 · 2019 · External reference
Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures
10.1186/s12935-022-02599-7 · 2022 · External reference
CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?
2023 · External reference
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
10.1158/0008-5472.can-03-2524 · 2004 · External reference
Strategies and challenges for the next generation of antibody-drug conjugates
10.1038/nrd.2016.268 · 2017 · External reference
Minireview: addressing the retro-Michael instability of maleimide bioconjugates
10.1016/j.ddtec.2018.07.002 · 2018 · External reference
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
2003 · External reference
A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model
10.1158/1535-7163.mct-17-0749 · 2018 · External reference
Early detection of cancer
10.1126/science.aay9040 · 2022 · External reference
New technologies for human cancer imaging
10.1200/jco.2007.14.3065 · 2008 · External reference
Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models
10.1158/0008-5472.can-15-1795 · 2016 · External reference
LRRC15 is a novel mesenchymal protein and stromal target for antibody–drug conjugates
10.1158/0008-5472.can-18-0327 · 2018 · External reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · 2023 · External reference
Microtubules as a target for anticancer drugs
10.1038/nrc1317 · 2004 · External reference
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors
2013 · External reference
Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
10.1007/s00428-018-2408-z · 2018 · External reference
Immunological hallmarks of stromal cells in the tumour microenvironment
10.1038/nri3902 · 2015 · External reference
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
10.1038/s41467-025-58266-8 · 2025 · External reference
Antibody-drug conjugates: recent advances in linker chemistry
10.1016/j.apsb.2021.03.042 · 2021 · External reference
Antibody-drug conjugates: recent advances in payloads
10.1016/j.apsb.2023.06.015 · 2023 · External reference
